Hod Hasharon, Israel

Shira Walach

This inventor holds 14 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Biologics Development. Top assignee: Compugen Ltd. Corporation. Active years: 2008-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shira Walach. Retrieved from https://idiyas.com/inventor/shira-walach

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14 

% Patents Active = 14.3

 

 

Average Co-Inventor Count = 13.1

ph-index = 6

Forward Citations = 200(Granted Patents)


Location History:

  • Hod-HaSahron, IL (2009)
  • Hod-HaSharon, IL (2008 - 2018)

Company Filing History:


Years Active: 2008-2018

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Polypeptides
Polynucleotides
Drug Target
Biologics
Diagnostic Markers
Ovarian Cancer
Cardiac Disease
Lung Cancer
Breast Cancer
In Vivo Imaging
Assays
Nucleotide Sequences
14 patents (USPTO):Explore Patents

Title: Shira Walach - Innovator in Therapeutic Antibodies

Introduction

Shira Walach is a prominent inventor based in Hod Hasharon, Israel, who has made significant contributions to the field of biomedicine. With a remarkable portfolio of 14 patents, Shira's work primarily focuses on novel therapeutic targets for the development of drugs and biologics.

Latest Patents

Shira's latest invention revolves around polypeptides and polynucleotides, which serve as drug targets for producing immune and non-immune-based therapeutics. This significant innovation involves therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32, or FXYD3 antigens. These antigens are identified as co-stimulatory family members, which show differential expression in various cancers, including lung cancer, ovarian cancer, and colon cancer. The patent details the use of these antibodies not only for cancer therapies but also for modulating B7 costimulation and related treatments for autoimmunity. Additionally, the invention discusses the discovery of extracellular domains of these targets, offering new avenues for immunotherapy and drug development.

Career Highlights

Shira Walach is currently associated with Compugen Ltd., a corporation dedicated to pioneering computational biology to enhance drug discovery and development. His expertise and innovative contributions have positioned him as a key figure in the continuous exploration of therapeutic possibilities in cancer treatment and diagnosis.

Collaborations

Shira has collaborated with notable professionals such as Zurit Levine and Amit Novik, leveraging their combined expertise to drive forward groundbreaking research in the field of biomedicine. Together, they work on enhancing the understanding and application of novel therapeutic antibodies, showcasing a collaborative spirit that fosters advancement in innovative solutions for health challenges.

Conclusion

Through his extensive portfolio of patents and collaborations, Shira Walach exemplifies a passionate and dedicated inventor in the realm of therapeutics. His work not only promises to contribute to the landscape of cancer treatment but also holds potential for improving disease diagnosis and immune modulation therapies. As research continues to evolve, Shira’s inventions are poised to play a crucial role in shaping the future of biomedical sciences.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…